XIMINO (minocycline hydrochloride) by Journey Medical is clinical pharmacology following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2. First approved in 2012.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
XIMINO is an extended-release oral capsule formulation of minocycline hydrochloride, a tetracycline-class antibiotic that inhibits bacterial protein synthesis. It is active against a broad spectrum of gram-positive and gram-negative bacteria, as well as atypical organisms including Chlamydia, Mycoplasma, and Rickettsia. The formulation achieves peak serum concentrations in 1-4 hours with a half-life of approximately 15.5 hours and may be taken with or without food.
Minimal commercial traction with only $35K in Part D spending and 33 claims in 2023 suggests a niche positioning with limited team expansion opportunities.
CLINICAL PHARMACOLOGY Following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 mcg/mL (average 3.5 mcg/mL). The serum…
Worked on XIMINO at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
XIMINO offers minimal career growth potential given its approaching loss of exclusivity, commodity market position, negligible commercial performance ($35K Part D spending), and absence of clinical development pipeline. Career roles on this product are largely focused on managing decline and transitioning assets rather than growth-oriented strategic work.